Amneal Pharmaceuticals (AMRX) Total Liabilities (2018 - 2026)

Amneal Pharmaceuticals' Total Liabilities history runs 9 years deep, the most recent figure standing at $3.6 billion for Q1 2026.

• In Q1 2026, Total Liabilities rose 2.54% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $3.6 billion (up 2.54% YoY), while the FY2025 annual figure was $3.7 billion, up 3.82% from the prior year.
• Total Liabilities was $3.6 billion for Q1 2026 at Amneal Pharmaceuticals, down from $3.7 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $3.9 billion in Q2 2022 to a low of $3.5 billion in Q4 2023.
• Historically, Total Liabilities has averaged $3.6 billion across 5 years, with a median of $3.6 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities climbed 6.49% in 2022, then retreated 8.23% in 2023.
• A 5-year view of Total Liabilities shows it stood at $3.6 billion in 2022, then dropped by 4.5% to $3.5 billion in 2023, then grew by 4.59% to $3.6 billion in 2024, then advanced by 3.82% to $3.7 billion in 2025, then decreased by 4.34% to $3.6 billion in 2026.
• The last three Total Liabilities figures came in at $3.6 billion (Q1 2026), $3.7 billion (Q4 2025), and $3.7 billion (Q3 2025), per Business Quant data.